Method and compounds for generation of iPSCs
The present invention is based on the seminal concept of combining genomics and chemical biology to identify new agents useful for induced pluripotent stem cell (iPSC) generation. The invention provides a method of generating an iPSC utilizing agents that antagonize a cell specific gene or upregulate expression or activity of a nuclear reprogramming gene, as well as a method of screening for such agents.
1. An in vitro method of generating an induced pluripotent stem cell (iPSC) comprising:
a) contacting a human or mouse fibroblast cell with nuclear reprogramming factors, the nuclear reprogramming factors being OCT4, SOX2, KLF4 and C-MYC, wherein the nuclear reprogramming factors are encoded by one or more polynucleotides; and
b) contacting the cell of (a) with an agent that inhibits COX-2 expression or activity, wherein the agent is a polynucleotide, and wherein reprogramming efficiency is increased as compared to generation of an iPSC without contacting the cell with the agent, thereby generating an iPS cell.
2. The method of claim 1 , wherein the nuclear reprogramming factors are contained in one or more recombinant vectors introduced into the cell.
3. The method of claim 2 , wherein the nuclear reprogramming factors further comprise SALL4, NANOG, L1N28 or a combination thereof.
4. The method of claim 1 , wherein the cell is contacted with the nuclear reprogramming factors prior to, simultaneously with or following contacting with the agent.
5. The method of claim 1 , wherein the nuclear reprogramming factors further comprise SALL4, NANOG, LIN28, or a combination thereof.
6. The method of claim 1 , wherein the method has a reprogramming efficiency that is increased by at least a factor of 2, 3, 4, 5, 6, 7, 8, 9, 10 or greater as compared to generation of an iPSC without contacting the cell with the agent.
7. An induced pluripotent stem cell (iPSC) produced using the method of claim 1 .
8. A population of induced pluripotent stem cells (iPSCs) produced by the method of claim 1 .
9. The method of claim 1 , wherein the polynucleotide of (b) is an antisense oligonucleotide, chemically modified oligonucleotides, locked nucleic acid (LNA), or DNA.
10. The method of claim 1 , wherein the polynucleotide of (b) is RNA.
11. The method of claim 10 , wherein the RNA is selected from the group consisting of microRNA, dsRNA, siRNA, stRNA, or shRNA.
12. The method of claim 11 , wherein the RNA is siRNA.